TekniPlex
TekniPlex Healthcare, which utilises advanced materials science expertise to help deliver better patient outcomes, will emphasise its broadened capabilities for the design and manufacture of Class III implantable devices and delivery systems at COMPAMED, November 11-14 in Düsseldorf, Germany.
At Hall 8b, Stand N02, the company will highlight its status as a full-fledged CDMO in these niches, one capable of partnering with startups and established entities alike on everything from initial concepting, prototyping and pilot production through larger-scale manufacturing and commercialisation.
The company also will showcase several recently introduced solutions, including bio-based PVC compounds and its most robust reinforced paper to date for medical device packaging applications.
TekniPlex Healthcare says it is among the few medical device CDMOs offering comprehensive, ideation-to-completion product creation across a wide range of categories including endovascular stents, heart valves and delivery systems.
The company also offers high-precision, tight-tolerance development and prototyping for the mission critical metal components typical in cardiovascular settings as well as pulmonary, gastrointestinal, laparoscopic and other endoscopic applications – including devices for delivering chemotherapy drugs.
TekniPlex Healthcare says it has become the first healthcare solutions company to introduce bio-based compounds for medical plastics applications whose performance and compositional properties are equivalent to conventional polyvinyl chloride (PVC) resins. Certified through the globally recognised International Sustainability & Carbon Certification PLUS (ISCC PLUS) system, the bio-based medical-grade PVC compounds utilise resins and plasticisers manufactured with renewable energy and bio-attributed classification.
The compounds are equivalent to traditional medical-grade PVC in terms of chemical composition, functionality and regulatory viability.
